Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Yuyao People's Hospital | OTHER |
| Taizhou Enze Medical Center Group | OTHER |
| Ningbo Medical Center Lihuili Hospital | OTHER_GOV |
| People's Hospital of Guangxi Zhuang Autonomous Region |
Not provided
Not provided
Not provided
Not provided
The goal of this clinical trial is to investigate whether methylene blue injection can safely and effectively improve the survival rate of patients with severe septic shock, shorten the duration of norepinephrine use, reduce the dosage of vasopressors, promptly correct hemodynamics, and improve tissue perfusion and organ function impairment.
Researchers will compare methylene blue to a placebo (a look-alike substance that contains no drug) to see if methylene blue works to treat severe septic shock.
Participants will:
Administer a loading dose of 2.5 mg/kg via micro-pump over 15 minutes, followed by a maintenance infusion at a rate of 0.25 mg/kg/hour for 12 hours or until norepinephrine has been continuously discontinued for 4 hours, whichever comes first. If norepinephrine needs to be increased to 0.25 μg/kg/min before the 12-hour period ends, continue using methylene blue until the 12-hour infusion is completed.
Primary Study Endpoint
- 28-day all-cause mortality rate starting from the diagnosis of septic shock.
Secondary Study Endpoints
Record the following indicators before methylene blue intervention and at 24 hours, 72 hours, and 5 days after the intervention:
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Methylene Blue Intervention Group | Experimental | Methylene blue injection, 2.5 mg/kg loading dose over 15 minutes, followed by a continuous infusion of 0.25 mg/kg/hour for 12 hours or until norepinephrine has been continuously discontinued for 4 hours, whichever comes first. |
|
| Normal Saline Control Group | Placebo Comparator | Normal saline solution, administered in the same manner and duration as the methylene blue intervention. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Methylene Blue Intervention Group | Drug | In addition to standard treatment, patients will receive methylene blue intervention. The method is as follows: a loading dose of 2.5 mg/kg administered via micro-pump over 15 minutes, followed by a continuous infusion at a rate of 0.25 mg/kg/hour for 12 hours or until norepinephrine has been continuously discontinued for 4 hours, whichever comes first. If norepinephrine needs to be increased to 0.1 μg/kg/min before the 12-hour period ends, continue using methylene blue until the 12-hour infusion is completed. |
| Measure | Description | Time Frame |
|---|---|---|
| 28-day survival rate of enrolled patients | Our primary endpoint is the 28-day survival rate of enrolled patients: All enrolled patients will be followed from the time of randomization until 28 days post-enrollment, recording the survival status on the 28th day after enrollment. If a patient dies within 28 days post-enrollment, the number of survival days will be recorded. Note:
| 28-day |
| Measure | Description | Time Frame |
|---|---|---|
| The duration and dosage of norepinephrine use | The duration of norepinephrine use：The time from the start of norepinephrine (NE) administration after sepsis diagnosis until its discontinuation. The definition of discontinuation: NE must be stopped for ≥2 hours; if NE is stopped for <2 hours, it is not considered discontinued. If NE is re-administered after being stopped for more than 2 hours, it is still considered discontinued. The dosage of norepinephrine use：the total dose of NE used within 72 hours after the patient is enrolled in the study. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Wenqiao Yu, PhD | Contact | +86-18868787588 | yuwenqiao1980@zju.edu.cn |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The First Affiliated Hospital, Zhejiang University School of Medicine | Recruiting | Hangzhou | Zhejiang | China |
You can explain the reason and contact the study initiator via email to request the data. The email address is:yuwenqiao1980@zju.edu.cn
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D012772 | Shock, Septic |
| D018805 | Sepsis |
| ID | Term |
|---|---|
| D007239 | Infections |
| D018746 | Systemic Inflammatory Response Syndrome |
| D007249 | Inflammation |
| D010335 | Pathologic Processes |
Not provided
Not provided
| OTHER |
| The second Nanning People's Hospital | UNKNOWN |
| GUI LIN PEOPLE'S HOSPITAL | UNKNOWN |
| First Affiliated Hospital, Sun Yat-Sen University | OTHER |
| The First People's Hospital of Huzhou | OTHER |
| Hangzhou Yuhang District Second People's Hospital | UNKNOWN |
| Wuming Hospital of Guangxi Medical University | UNKNOWN |
This is a prospective, randomized, controlled, single-blind study.
Not provided
Not provided
This study implements blinding for the outcome assessor.
|
| Normal Saline Control Group | Drug | In addition to standard treatment, patients will receive a placebo control with normal saline, administered for the same duration as the intervention group. |
|
| 28-day |
| The duration of mechanical ventilation | The number of days without mechanical ventilation within 28 days post-enrollment. Note: Only full days without mechanical ventilation can be counted as one day. | 28-day |
| The duration of ICU stay | ICU length of stay: the number of days in the ICU starting from the time of patient enrollment in the study. Note: Some patients may have multiple ICU admissions; only the ICU stay duration after the current enrollment is recorded. | 28-day |
| The duration of overall hospital stay | The duration of overall hospital stay: the total number of days hospitalized starting from the time of patient enrollment in the study. Note: Days hospitalized prior to enrollment are not included. | 28-day |
| The safety of methylene blue injection | We will record the complications due to the use of methylene blue, such as hemolysis: We will determine the presence of hemolysis by daily monitoring of urine color, red blood cells, hemoglobin count in complete blood count, and bilirubin levels in liver function tests. If the patient's urine turns dark brown (similar to soy sauce), accompanied by a decrease in hemoglobin and red blood cell count and a simultaneous increase in bilirubin, hemolysis will be considered. | 28-day |
| D013568 |
| Pathological Conditions, Signs and Symptoms |
| D012769 | Shock |